Acquisition provides highly differentiated clinical-stage treatment for prostate cancer, building on Johnson & Johnson’s nearly two decades of innovation in the disease area
Johnson & Johnson announced that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months, subject to antitrust clearance and other customary closing conditions.
Health Technology Insights: Atomic Launches Model to Guide MedTech Startups from Vision to Venture
The lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer, of which new diagnoses are projected to reach 1.7 million globally by 2030. Given the existing unmet need, this once-daily therapy has the potential to transform patient outcomes with its novel precision cancer cell-killing approach that can overcome mechanisms of resistance to treatment. The acquisition also includes several earlier candidates for breast, lung and multiple other tumor types. Halda’s pipeline and platform may also enable the creation of novel targeted therapies beyond oncology.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 12 November 2025
“This acquisition further strengthens our deep oncology pipeline with an exciting lead asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncology, providing a potential mid- and long-term catalyst for growth,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson. “We look forward to combining Halda’s pipeline, platform and people with our world class R&D, commercial and manufacturing capabilities and advancing our goal of bringing these therapies to patients around the world.”
“Many therapies lose effectiveness over time due to resistance. Halda’s innovative technology is designed to work even when cancers no longer respond to standard treatments using a novel mechanism that enables the selective killing of cancer cells,” said John C. Reed, M.D., Ph.D.,Executive Vice President, Innovative Medicine, R&D, Johnson & Johnson. “Results seen with HLD-0915 demonstrate impressive preliminary efficacy and a strong early safety profile in prostate cancer. We are eager to accelerate the ongoing Phase 1/2 clinical trial of HLD-0915 and progress a pipeline of novel product candidates based on RIPTAC technology.”
The planned acquisition underscores Johnson & Johnson’s longstanding commitment to prostate cancer and industry-leading oncology portfolio, adding new therapies with novel and complementary mechanisms of action. Halda’s pipeline of differentiated assets, if successful, will provide critical new options for patients.
Health Technology Insights: Cityblock Health and Mercy Health Align to Serve Medicaid Members in Ohio
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
